Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 4/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.32 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3861841 | 0.80 | CYP2A6 (0.42) | ELANEALDH1A1CYP1A2KDM4EMAPT | |
| SCHEMBL7954562 | 0.75 | NR4A2 (0.41) | ALDH1A1CYP1A2KDM4ELMNAPSMD14 | |
| SCHEMBL7952608 | 0.75 | AR (0.36) | ALDH1A1CYP1A2KDM4EHTTPSMD14 | |
| SCHEMBL7954070 | 0.72 | NQO2 (0.42) | ALDH1A1KDM4EMAPTHPGDHSD17B10 | |
| SCHEMBL3272867 | 0.71 | PSMD14 (0.58) | ELANEGABRA1GABRB2ALDH1A1CYP1A2 | |
| SCHEMBL5751117 | 0.67 | TNKS2 (0.40) | ELANEALDH1A1CYP1A2KDM4EMAPT | |
| SCHEMBL411657 | 0.66 | CYP1A2 (0.45) | ALDH1A1CYP1A2KDM4EMAPTHPGD | |
| SCHEMBL3238496 | 0.65 | GABRA1 (0.57) | GABRA1GABRB2ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL599157 | 0.65 | CYP1A2 (0.62) | GABRA1GABRB2ALDH1A1CYP1A2TSHR | |
| SCHEMBL8272632 | 0.65 | MAPT (0.43) | ELANEGABRA1GABRB2ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040204451-A1 | Method for treating retroviral infections | UNIROYAL CHEMICAL COMPANY, INC., A CORPORATION OF THE STATE OF DELAWARE | 2004-10-14 | — | — | US | claimed |
| US-20040132778-A1 | Method for treating retroviral infections | UNIROYAL CHEMICAL COMPANY INC., A CORPORATION OF THE STATE OF DELAWARE | 2004-07-08 | — | — | US | claimed |
| US-20030139445-A1 | Method for treating retroviral infections | BIOLAB, INC. | 2003-07-24 | — | — | US | claimed |
| WO-2003037311-A2 | METHOD FOR TREATING RETROVIRAL INFECTIONS | UNIROYAL CHEMICAL COMPANY, INC. (US) | 2003-05-08 | — | — | WO | claimed |
| US-7064139-B2 | Method for treating retroviral infections | UNIROYAL CHEMICAL COMPANY, INC. (US) | 2006-06-20 | — | — | US | disclosed |
| US-20040204451-A1 | Method for treating retroviral infections | UNIROYAL CHEMICAL COMPANY, INC., A CORPORATION OF THE STATE OF DELAWARE | 2004-10-14 | — | — | US | disclosed |
| US-20040132778-A1 | Method for treating retroviral infections | UNIROYAL CHEMICAL COMPANY INC., A CORPORATION OF THE STATE OF DELAWARE | 2004-07-08 | — | — | US | disclosed |
| US-20030139445-A1 | Method for treating retroviral infections | BIOLAB, INC. | 2003-07-24 | — | — | US | disclosed |
| WO-2003037311-A2 | METHOD FOR TREATING RETROVIRAL INFECTIONS | UNIROYAL CHEMICAL COMPANY, INC. (US) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204451-A1 | Method for treating retroviral infections | TPMT, ALB, GARS1 | ELANE 2649/4885GABRA1 1618/4885GABRB2 1810/4885 |
| US-20030139445-A1 | Method for treating retroviral infections | TPMT, ALB, GARS1 | ELANE 2649/4885GABRA1 1618/4885GABRB2 1810/4885 |
| US-20040132778-A1 | Method for treating retroviral infections | TPMT, TYMP, ARSA | ELANE 2533/4885GABRA1 930/4885GABRB2 866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.